EpiPen Pricing
written by Michael H. Moffett, fl. 2011 (Glendale, AZ: Thunderbird Global School of Management, 2017, originally published 2017), 15 page(s)
Details
- Abstract / Summary
- Mylan and its CEO, Heather Bresch, were under attack for a multitude of large price increases in their life-saving pharmaceutical, the EpiPen. The U.S. Congress, the Federal Drug Administration (FDA), and millions of people considered at risk and in need of access to EpiPen injectors, wanted to know why and how those price increases had happened. This case has been used in both graduate business and management degree and non-degree programs to provide a platform for discussions of a number of differing issues, including pharmaceutical pricing and what justifies price increases, how to create demand for a product, whether pharmaceutical firms should share price maximization objectives at a potential cost in customer access, and what role corporate compensation policy plays in business performance. It can also serve as a foundation on how to or how not to handle public criticism of corporate business policies.
- Field of Interest
- Business & Economics
- Author
- Michael H. Moffett, fl. 2011
- Copyright Message
- Copyright © 2017 Thunderbird School of Global Management, a unit of the Arizona State University Knowledge Enterprise.
- Content Type
- Case study
- Duration
- 0 sec
- Format
- Text
- Original Publication Date
- 2017
- Page Count
- 15
- Publication Year
- 2017
- Publisher
- Thunderbird Global School of Management
- Place Published / Released
- Glendale, AZ
- Subject
- Business & Economics, Social Sciences, Corporate Governance, Drugs and pharmaceuticals, Medications, Prices, Pharmaceutical and Medicine Manufacturing, Governança Corporativa, Gobierno Corporativo, United States of America, USA, US of A, America, Estados Unidos, Mylan, Heather Bresch, 1969-, United States
- Keywords and Translated Subjects
- Governança Corporativa, Gobierno Corporativo, United States of America, USA, US of A, America, Estados Unidos
